One such industry is healthcare. And here are two healthcare stocks to consider for diversification, if you are heavily ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

A new report indicates that U.S. drugmakers will raise prices on at least 350 medications despite pressure from President ...

The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is ...

A bill to implement state-level enforcement of federal hospital price transparency requirements in Wisconsin, with the goal ...

Most Americans likely will not benefit immediately from efforts to lower prescription prices. Administration officials expect ...

A health and national security cess and excise duty on pan masala and tobacco products respectively will be over and above 40 ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration ...

The price hikes come even as the Trump administration pressures pharmaceutical companies to lower costs for patients and ...

Trump promised in 2025 to send out the checks "probably in the middle of next year," or "a little bit later than that," while billing them as dividends or "tariff rebate checks" as he aims to show the ...

Bernstein analyst Lance Wilkes discusses the outlook for the managed care providers in 2026, and how they and the Trump administration can best address spiking healthcare costs. 'Robbing them': ...